Aug 05 2014 TheraDoc is a wholly owned subsidiary of Hospira NYSE HSP Premier s board of directors unanimously approved the transaction and applicable antitrust approvals have already been obtained Based on the trailing twelve months operating earnings provided by TheraDoc the 117 million represents a purchase price multiple in the 10 11 times range
The proposed acquisition of Hospira demonstrates our commitment to prudently deploy capital to create shareholder value and deliver incremental revenue and EPS growth in the near term said Ian Read Chairman and Chief Executive Officer Pfizer In
Sep 03 2015 September 03 2015 09 00 AM Eastern Daylight Time NEW YORK BUSINESS WIRE Pfizer Inc NYSE PFE today announced that it has
Hospira completes acquisition of Orchid s generic injectables business 31 Mar 2010 Finance Gains new manufacturing capabilities and expands global reach Hospira has completed its US 400m takeover of the dosage forms business of Orchid Chemicals Pharmaceuticals of India
Sep 05 2015 Pfizer completes acquisition of Hospira We are pleased that Hospira the world s leading provider of injectable drugs and infusion technologies and
Sep 03 2015 Thursday September 3 20159 00am EDT Pfizer Inc NYSE PFE today announced that it has completed its acquisition of Hospira Inc We are pleased that Hospira the world s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars is now part of Pfizer We want to welcome our new Hospira
Aug 10 2015 Merger Acquisition Deal Analysis 1 Valuation Investment Banking Advisory Services M A DEAL ANALYSIS PFIZER ACQUISITION OF HOSPIRA INC Contents 1 Deal Synopsis 2 Companies Involved in the Merger 3 Proposed Deal Structure 4 Rational for Acquisition 5 Financial and other Implications 6
Sep 07 2015 Summary The acquisition of Hospira will bring a new set of generic product offerings to Pfizer The new products will add revenue immediately creating incremental shareholder value in the
Feb 05 2015 The proposed acquisition of Hospira demonstrates our commitment to prudently deploy capital to create shareholder value and deliver incremental revenue and EPS earnings per share growth in the near term Pfizer Chairman and Chief Executive Officer Ian Read said
Apr 09 2015 Pfizer US pharma giant Pfizer said it has completed the 17 billion acquisition of Hospira following which To continue reading The Pharma Letter please login subscribe or claim a 7 day free trial subscription and access exclusive features interviews round ups and commentary from the sharpest minds in the pharmaceutical and
Aug 05 2014 Premier Inc Continues Growth Trajectory With Acquisition of Hospira s TheraDoc Expanding Industry Leading Electronic Clinical Surveillance Solutions to Approximately 1 000 Facilities August 5 2014 Download this Press Release PDF 19 KB
ICU Medical will acquire all of Pfizer s global infusion therapy business Hospira Infusion Systems HIS for billion in cash and stock The Hospira Infusion Systems business includes IV pumps solutions and devices that when combined with ICU Medical s existing businesses will create a leading pure play infusion therapy company with estimated pro forma combined revenues of
Feb 10 2015 By Jim Miller Note This guest post by Jim Miller previously appeared in the PharmSource blog Pfizer s announcement that it will acquire Hospira sent a ripple through the pharmaceutical industry but a wave through the CMO industry At a time when the injectables pipeline is expanding thanks to biologics and oncology candidates a significant change in One2One s involvement in the
Feb 05 2015 Shares of Hospira soared 22 79 or 35 1 percent to 87 59 in premarket trading about a half hour before the market open while Pfizer s stock added 1 08 or 3 4 percent to
Sep 04 2015 The acquisition also means uncertainty over the fate of Hospira s recently PBAC recommended biosimiliar infliximab INFLECTRA The PBAC recommended INFLECTRA with an a flag which would allow pharmacy level substitution Pfizer s publicly stated global policy position is to oppose substitution of biosimilars and their reference biologic
Sep 03 2015 Pfizer completes 17bn acquisition of Hospira 03 Sep 2015 Pfizer is expanding its product offerings in a growing medical market with the acquisition of Hospira a US based provider of injectable drugs and infusion technologies for approximately 17bn
The acquisition of TheraDoc aligns well with Hospira s focus on improving the clinical outcomes caregiver productivity and safety of patient care said Philip Settimi M D vice president Global Marketing Devices Hospira TheraDoc is the gold standard in enterprise wide clinical surveillance and decision support
On October 31 2006 Hospira completed the acquisition of all outstanding shares of BresaGen Limited BresaGen formerly an Australian public company listed on the Australian Stock Exchange for 17 1 million in cash including transition costs BresaGen is a biotechnology company that develops protein and peptide therapeutics
Sep 08 2021 Hospira Acquisition October 6 2016 Earnings Adjustment August 7 2019 Pursuit Vascular Acquisition November 4 2019 > Focused on commercial execution > Diversified customer base > Warm up M A > Acquired Hospira Infusion Systems > Benefitted from IV solutions shortage
Sep 18 2015 The Hospira acquisition does contain a speculative element of high future growth Hospira sells many lower priced generic version of costly
Apr 20 2010 Hospira and Javelin Pharmaceuticals to merge 20 Apr 2010 Finance Hospira will initiate tender offer to acquire Javelin US pharmaceutical and drug delivery company Hospira and Javelin Pharmaceuticals have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for US 145m
Pfizer said in a statement that its acquisition of Hospira will create a leading global sterile injectables business The company estimates that the global market values for generic sterile injectables and biosimilars copycat versions of biological drugs will be 70 billion and 20 billion respectively in
Hospira Net Cash Flow Investment Acquisitions and Disposals is very stable at the moment as compared to the past year Hospira reported last year Net Cash Flow Investment Acquisitions and Disposals of 230 Million Analyze Hospira Net Cash Flow Investment Acquisitions and Disposals
Jul 04 2014 The acquisition enables Hospira already a leader in certain critical antibiotic injectable products to vertically integrate into the beta lactam antibiotic APIs penems and penicillins and is
Feb 06 2015 The proposed acquisition of Hospira demonstrates our commitment to prudently deploy capital to create shareholder value and deliver incremental revenue and EPS growth in the near term said Ian Read Chairman and Chief Executive Officer Pfizer In addition Hospira s business aligns well with our new commercial structure and is an excellent
Hospira was originally the hospital products division of Abbott and became an independent company in 2004 In the interim between its spin off from Abbott and its acquisition by Pfizer in 2015 Hospira acquired Mayne Pharma TheraDoc Javelin Pharmaceuticals and
Aug 31 2015 The Federal Trade Commission Commission has accepted subject to final approval an Agreement Containing Consent Orders Consent Agreement from Pfizer Inc Pfizer and Hospira Inc Hospira that is designed to remedy the anticompetitive effects resulting from Pfizer s acquisition of
Oct 13 2008 This acquisition represents an important extension of Hospira s commitment to improved outcomes patient safety and enhanced clinician efficiency said Chris Kolber president Global
Aug 24 2015 Pfizer said U S regulators have approved its acquisition of smaller rival Hospira pending the divestiture of some sterile injectable drugs putting the
Hospira Inc is the provider of injectable drugs and infusion technologies Through its broad integrated portfolio Hospira is uniquely positioned to Advance Wellness by improving patient and caregiver safety while reducing healthcare costs The company is headquartered in Lake Forest Ill and has approximately 16 000 employees
hospira mayne to sell five products to get acquisition approval January 22 2007 The U S FTC is set to approve a plan proposed by Hospira to acquire Australia based Mayne Pharma for 2 billion as long as certain conditions are met the agency has announced
Pfizer has an approximately 45 market share while Hospira has a 39 share The Acquisition would reduce the number of suppliers from four to three and increase the HHI by 3 562 points resulting in a post acquisition HHI of 7 276 points 9 Voriconazole injection is an antifungal medication used to treat significant fungal infections
Hospira the world s leading provider of injectable drugs and infusion technologies had evolved rapidly since spinning off from Abbot Laboratories To sell a broadening portfolio that now included comprehensive medication management solutions Hospira s major account executives and corporate national account executives needed to
Feb 06 2017 The Hospira Infusion Systems acquisition complements ICU Medical s existing business to create a company with a complete I V therapy product portfolio from solutions to pumps to non dedicated infusion sets In addition the acquisition gives ICU Medical a significantly enhanced global footprint and platform for continued competitiveness and
Feb 05 2015 The proposed acquisition of Hospira demonstrates our commitment to prudently deploy capital to create shareholder value and deliver incremental revenue